Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions

Journal of Immunology

Volumn 194, Issue 11, 2015, Pages 5497-5508

  Grevys, Algirdas ^a,b   Bern, Malin ^a,b   Foss, Stian ^a,b   Bratlie, Diane Bryant ^c   Moen, Anders ^a   Gunnarsen, Kristin Støen ^a,b   Aase, Audun ^c   Michaelsen, Terje Einar ^a,c   Sandlie, Inger ^a,b   Andersen, Jan Terje ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 FC FRAGMENT; UNCLASSIFIED DRUG; 4 HYDROXY 3 IODO 5 NITROPHENYLACETIC ACID; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIBODY DEPENDENT COMPLEMENT MEDIATED CELL LYSIS; ANTIBODY ENGINEERING; ARTICLE; BINDING AFFINITY; COMPLEMENT FIXATION; CONTROLLED STUDY; CYTOLYSIS; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; ANTIBODY AFFINITY; CELL LINE; GENETICS; HEK293 CELL LINE; HINGE EXON; IMMUNOLOGY; PROTEIN ENGINEERING; SURFACE PLASMON RESONANCE;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; COMPLEMENT C1Q; HEK293 CELLS; HINGE EXONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; NITROHYDROXYIODOPHENYLACETATE; PHAGOCYTOSIS; PROTEIN ENGINEERING; RECEPTORS, FC; RECEPTORS, IGG; SURFACE PLASMON RESONANCE;

EID: 84929649892     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401218     Document Type: Article

References (70)

1. Chan, A. C., and P. J. Carter. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10: 301-316.
2. Weiner, L. M., R. Surana, and S. Wang. 2010. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10: 317-327.
3. Idusogie, E. E., L. G. Presta, H. Gazzano-Santoro, K. Totpal, P. Y. Wong, M. Ultsch, Y. G. Meng, and M. G. Mulkerrin. 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164: 4178-4184.
4. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
5. Natsume, A., M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, and R. Niwa. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68: 3863-3872.
6. Richards, J. O., S. Karki, G. A. Lazar, H. Chen, W. Dang, and J. R. Desjarlais. 2008. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7: 2517-2527.
7. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J. Biol. Chem. 276: 6591-6604.
8. Hogarth, P. M., and G. A. Pietersz. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11: 311-331.
9. Alegre, M. L., L. J. Peterson, D. Xu, H. A. Sattar, D. R. Jeyarajah, K. Kowalkowski, J. R. Thistlethwaite, R. A. Zivin, L. Jolliffe, and J. A. Bluestone. 1994. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57: 1537-1543.
10. Woodle, E. S., D. Xu, R. A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L. K. Jollife, T. Haverty, J. A. Bluestone, and J. R. Thistlethwaite, Jr. 1999. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3g1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68: 608-616.
11. Bolt, S., E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S. D. Gorman, M. Clark, and H. Waldmann. 1993. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23: 403-411.
12. Reddy, M. P., C. A. Kinney, M. A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P. R. Dal Monte, M. L. Doyle, M. R. Brigham-Burke, D. Anderson, et al. 2000. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164: 1925-1933.
13. Rother, R. P., S. A. Rollins, C. F. Mojcik, R. A. Brodsky, and L. Bell. 2007. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25: 1256-1264.
14. Jefferis, R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8: 226-234.
15. Shields, R. L., J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. Weikert, and L. G. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277: 26733-26740.
16. Umaña, P., J. Jean-Mairet, R. Moudry, H. Amstutz, and J. E. Bailey. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity. Nat. Biotechnol. 17: 176-180.
17. Morell, A., W. D. Terry, and T. A. Waldmann. 1970. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49: 673-680.
18. Stapleton, N. M., J. T. Andersen, A. M. Stemerding, S. P. Bjarnarson, R. C. Verheul, J. Gerritsen, Y. Zhao, M. Kleijer, I. Sandlie, M. de Haas, et al. 2011. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun. 2: 599.
19. Roopenian, D. C., and S. Akilesh. 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715-725.
20. Ward, E. S., and R. J. Ober. 2009. Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv. Immunol. 103: 77-115.
21. Akilesh, S., G. J. Christianson, D. C. Roopenian, and A. S. Shaw. 2007. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol. 179: 4580-4588.
22. Kobayashi, K., S. W. Qiao, M. Yoshida, K. Baker, W. I. Lencer, and R. S. Blumberg 2009. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 137: 1746-1756.e1.
23. Montoyo, H. P., C. Vaccaro, M. Hafner, R. J. Ober, W. Mueller, and E. S. Ward. 2009. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. USA 106: 2788-2793.
24. Ober, R. J., C. Martinez, C. Vaccaro, J. Zhou, and E. S. Ward. 2004. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J. Immunol. 172: 2021-2029.
25. Qiao, S. W., K. Kobayashi, F. E. Johansen, L. M. Sollid, J. T. Andersen, E. Milford, D. C. Roopenian, W. I. Lencer, and R. S. Blumberg. 2008. Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. USA 105: 9337-9342.
26. Ober, R. J., C. Martinez, X. Lai, J. Zhou, and E. S. Ward. 2004. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl. Acad. Sci. USA 101: 11076-11081.
27. Prabhat, P., Z. Gan, J. Chao, S. Ram, C. Vaccaro, S. Gibbons, R. J. Ober, and E. S. Ward. 2007. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc. Natl. Acad. Sci. USA 104: 5889-5894.
28. Dall'Acqua, W. F., R. M. Woods, E. S. Ward, S. R. Palaszynski, N. K. Patel, Y. A. Brewah, H. Wu, P. A. Kiener, and S. Langermann. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169: 5171-5180.
29. Ghetie, V., S. Popov, J. Borvak, C. Radu, D. Matesoi, C. Medesan, R. J. Ober, and E. S. Ward. 1997. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15: 637-640.
30. Hinton, P. R., M. G. Johlfs, J. M. Xiong, K. Hanestad, K. C. Ong, C. Bullock, S. Keller, M. T. Tang, J. Y. Tso, M. Vásquez, and N. Tsurushita. 2004. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279: 6213-6216.
31. Hinton, P. R., J. M. Xiong, M. G. Johlfs, M. T. Tang, S. Keller, and N. Tsurushita. 2006. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176: 346-356.
32. Kim, J. K., M. Firan, C. G. Radu, C. H. Kim, V. Ghetie, and E. S. Ward. 1999. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29: 2819-2825.
33. Petkova, S. B., S. Akilesh, T. J. Sproule, G. J. Christianson, H. Al Khabbaz, A. C. Brown, L. G. Presta, Y. G. Meng, and D. C. Roopenian. 2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 18: 1759-1769.
34. Vaccaro, C., J. Zhou, R. J. Ober, and E. S. Ward. 2005. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23: 1283-1288.
35. Dall'Acqua, W. F., P. A. Kiener, and H. Wu. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281: 23514-23524.
36. Simister, N. E., and K. E. Mostov. 1989. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb. Symp. Quant. Biol. 54: 571-580.
37. Burmeister,W. P., A. H. Huber, and P. J. Bjorkman. 1994. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372: 379-383.
38. West, A. P., Jr., and P. J. Bjorkman. 2000. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39: 9698-9708.
39. Patel, D. A., A. Puig-Canto, D. K. Challa, H. Perez Montoyo, R. J. Ober, and E. S. Ward. 2011. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J. Immunol. 187: 1015-1022.
40. Challa, D. K., U. Bussmeyer, T. Khan, H. P. Montoyo, P. Bansal, R. J. Ober, and E. S. Ward. 2013. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. MAbs 5: 655-659.
41. Zalevsky, J., A. K. Chamberlain, H. M. Horton, S. Karki, I. W. Leung, T. J. Sproule, G. A. Lazar, D. C. Roopenian, and J. R. Desjarlais. 2010. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28: 157-159.
42. Vaccaro, C., R. Bawdon, S. Wanjie, R. J. Ober, and E. S. Ward. 2006. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc. Natl. Acad. Sci. USA 103: 18709-18714.
43. Andersen, J. T., S. Foss, V. E. Kenanova, T. Olafsen, I. S. Leikfoss, D. C. Roopenian, A. M. Wu, and I. Sandlie. 2012. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J. Biol. Chem. 287: 22927-22937.
44. Kenanova, V., T. Olafsen, D. M. Crow, G. Sundaresan, M. Subbarayan, N. H. Carter, D. N. Ikle, P. J. Yazaki, A. F. Chatziioannou, S. S. Gambhir, et al. 2005. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 65: 622-631.
45. Norderhaug, L., T. Olafsen, T. E. Michaelsen, and I. Sandlie. 1997. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J. Immunol. Methods 204: 77-87.
46. Berntzen, G., E. Lunde, M. Flobakk, J. T. Andersen, V. Lauvrak, and I. Sandlie. 2005. Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J. Immunol. Methods 298: 93-104.
47. Michaelsen, T. E., I. Sandlie, D. B. Bratlie, R. H. Sandin, and O. Ihle. 2009. Structural difference in the complement activation site of human IgG1 and IgG3. Scand. J. Immunol. 70: 553-564.
48. Firan, M., R. Bawdon, C. Radu, R. J. Ober, D. Eaken, F. Antohe, V. Ghetie, and E. S. Ward. 2001. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of g-globulin in humans. Int. Immunol. 13: 993-1002.
49. Popov, S., J. G. Hubbard, J. Kim, B. Ober, V. Ghetie, and E. S. Ward. 1996. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol. Immunol. 33: 521-530.
50. Christianson, G. J., V. Z. Sun, S. Akilesh, E. Pesavento, G. Proetzel, and D. C. Roopenian. 2012. Monoclonal antibodies directed against human FcRn and their applications. MAbs 4: 208-216.
51. Aase, A., and T. E. Michaelsen. 1991. The use of a hapten-Fab conjugate to sensitize target cells for antibody-dependent complement-mediated lysis and antibodydependent cell-mediated cytotoxicity. J. Immunol. Methods 136: 185-191.
52. Aase, A., and T. E. Michaelsen. 1994. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39: 581-587.
53. Niesen, F. H., H. Berglund, and M. Vedadi. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2: 2212-2221.
54. Radaev, S., S. Motyka, W. H. Fridman, C. Sautes-Fridman, and P. D. Sun. 2001. The structure of a human type III Fcg receptor in complex with Fc. J. Biol. Chem. 276: 16469-16477.
55. Rose,R. J., P.H. vanBerkel,E.T. van denBremer, A. F. Labrijn, T. Vink, J. Schuurman, A. J. Heck, and P. W. Parren. 2013. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs 5: 219-228.
56. Vidarsson, G., A. M. Stemerding, N. M. Stapleton, S. E. Spliethoff, H. Janssen, F. E. Rebers, M. de Haas, and J. G. van de Winkel. 2006. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 108: 3573-3579.
57. Derer, S., P. Glorius, M. Schlaeth, S. Lohse, K. Klausz, U. Muchhal, J. R. Desjarlais, A. Humpe, T. Valerius, and M. Peipp. 2014. Increasing FcgRIIa affinity of an FcgRIII-optimized anti-EGFR antibody restores neutrophilmediated cytotoxicity. MAbs 6: 409-421.
58. Golay, J., F. Da Roit, L. Bologna, C. Ferrara, J. H. Leusen, A. Rambaldi, C. Klein, and M. Introna. 2013. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122: 3482-3491.
59. Diebolder, C. A., F. J. Beurskens, R. N. de Jong, R. I. Koning, K. Strumane, M. A. Lindorfer, M. Voorhorst, D. Ugurlar, S. Rosati, A. J. Heck, et al. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343: 1260-1263.
60. Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcgRIII complex. Nature 406: 267-273.
61. Schneider, S., and M. Zacharias. 2012. Atomic resolution model of the antibody Fc interaction with the complement C1q component. Mol. Immunol. 51: 66-72.
62. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
63. Oganesyan, V., M. M. Damschroder, R. M. Woods, K. E. Cook, H. Wu, and W. F. Dall'acqua. 2009. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol. Immunol. 46: 1750-1755.
64. Jung, S. T., S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, and G. Georgiou. 2010. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. USA 107: 604-609.
65. Borrok, M. J., S. T. Jung, T. H. Kang, A. F. Monzingo, and G. Georgiou. 2012. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 7: 1596-1602.
66. Frank, M., R. C. Walker, W. N. Lanzilotta, J. H. Prestegard, and A. W. Barb. 2014. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J. Mol. Biol. 426: 1799-1811.
67. Peters, R. T., G. Toby, Q. Lu, T. Liu, J. D. Kulman, S. C. Low, A. J. Bitonti, and G. F. Pierce. 2013. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J. Thromb. Haemost. 11: 132-141.
68. Shapiro, A. D., M. V. Ragni, R. Kulkarni, J. Oldenberg, A. Srivastava, D. V. Quon, K. J. Pasi, H. Hanabusa, I. Pabinger, J. Mahlangu, et al. 2014. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J. Thromb. Haemost. 12: 1788-1800.
69. Thompson, C. A. 2014. New hemophilia A treatment allows less-frequent prophylactic doses. Am. J. Health Syst. Pharm. 71: 1153.
70. Saphire, E. O., P. W. Parren, R. Pantophlet, M. B. Zwick, G. M. Morris, P. M. Rudd, R. A. Dwek, R. L. Stanfield, D. R. Burton, and I. A. Wilson. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159.